Italy cancels marketing approval for Salbutamolo Sandoz at company's request
Italy's medicines agency AIFA has published an official notice cancelling the marketing permission for Salbutamolo Sandoz, a human medicine. The license holder asked for the cancellation and gave up its authorization, and the notice appeared in the Gazzetta Ufficiale on 31 October 2026. The excerpt does not say when the medicine will stop being sold.
This summary was generated by AI; the official source prevails.
What does it mean?
Salbutamolo Sandoz is a medicine that was officially allowed to be sold in Italy, and that permission has now been cancelled. The company that held the permission asked for this itself. Patients and pharmacies should check with their doctor or pharmacist about alternatives if they rely on this product.
Who is affected?
Patients who use Salbutamolo Sandoz and the pharmacies and doctors who supply or prescribe it in Italy.